Oh WOW! Validation in clinical research on PromarkerD & potentially treatments available very soon in Europe with EMA application for Invokana (Canagliflozin).
SLGT2 Inhibitor class of drugs, with the race on for AstraZenica, Boehringer/Eli Lilly & Johnson & Johnson/Janssen whom PIQ have a collaboration with on completed clinical trial samples, which I’m sure will benefit both Companies & worth the wait. First in line with FDA.
CV indications as well as CKD maybe on the cards. ANNs seem to be coming thick & fast, we aren’t even there yet for timeline for Janssen & FDA application for USA. It’s really exciting, what is coming out of the Labs for PIQ.
I think my cheeky post might have been warranted this morning. GLTAH
PIQ Price at posting:
33.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)